NASDAQ:GLMD

Galmed Pharmaceuticals Stock Forecast, Price & News

$3.03

+0.03 (+1.00 %)

(As of 06/23/2021 04:30 PM ET)

Add

Compare

Today's Range

$2.95

▼

$3.05

50-Day Range

$2.24

▼

$3.90

52-Week Range

$2.15

▼

$6.29

Volume163,541 shs

Average Volume360,708 shs

Market Capitalization$76.00 million

P/E RatioN/A

Dividend YieldN/A

Beta2.17

30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

-$0.41 EPS Expected for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) This Quarter
June 18, 2021 | americanbankingnews.com

Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD)
June 7, 2021 | nasdaq.com

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Consensus Rating of "Buy" by Analysts
June 7, 2021 | americanbankingnews.com

Why Penny Stock Galmed Pharma Is A “Strong Buy” With Triple-Digit Upside?
June 4, 2021 | nasdaq.com

Why Is Penny Stock Galmed Pharma A “Strong Buy” With Triple-Digit Upside?
June 4, 2021 | finance.yahoo.com

-$0.41 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) This Quarter
May 31, 2021 | americanbankingnews.com

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 15, 2021 | nasdaq.com

Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
May 13, 2021 | finance.yahoo.com

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
May 3, 2021 | finance.yahoo.com

Galmed Pharmaceuticals(GLMD)
April 18, 2021 | fool.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
Previous Symbol
CUSIPN/A
CIK1595353
Webwww.galmedpharma.com
Phone972-3693-8448
Employees18
Year FoundedN/A

Sales & Book Value

Annual Sales$2.04 million
Price / Sales37.26
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.09 per share
Price / Book1.45

Profitability

EPS (Most Recent Fiscal Year)($1.35)
Net Income$-28,770,000.00
Net MarginsN/A
Return on Equity-60.07%
Return on Assets-53.27%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares25,084,000
Market Cap$76.00 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.47 out of 5 stars

Medical Sector

641st out of 2,105 stocks

Pharmaceutical Preparations Industry

311th out of 832 stocks

3.4 Analyst's Opinion

Consensus Rating
Galmed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, Galmed Pharmaceuticals has a forecasted upside of 630.9% from its current price of $3.01.
Amount of Analyst Coverage
Galmed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Galmed Pharmaceuticals has received 439 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Galmed Pharmaceuticals has received 233 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Galmed Pharmaceuticals has received 65.33% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote “Outperform” if you believe GLMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Galmed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Galmed Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 22.57% of the stock of Galmed Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Galmed Pharmaceuticals are expected to grow in the coming year, from ($1.56) to ($1.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galmed Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galmed Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galmed Pharmaceuticals has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galmed Pharmaceuticals stock.
View analyst ratings for Galmed Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Galmed Pharmaceuticals.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its quarterly earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06.
View Galmed Pharmaceuticals' earnings history.

How has Galmed Pharmaceuticals' stock been impacted by Coronavirus?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLMD shares have decreased by 28.0% and is now trading at $3.03.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GLMD?

5 Wall Street analysts have issued 1 year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $14.00 to $33.00. On average, they expect Galmed Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 626.1% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:

Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 56, Pay $766.58k)
Mr. Yohai Stenzler, Chief Financial Officer (Age 38, Pay $167.26k)
Mr. Guy Nehemya, Chief Operating Officer (Age 36, Pay $167.54k)
Dr. Liat Hayardeny, Chief Scientific Officer (Age 54, Pay $215.45k)
Dr. Tali Gorfine, Medical Consultant (Age 51, Pay $202.76k)
Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 38)

Who are some of Galmed Pharmaceuticals' key competitors?

Some companies that are related to Galmed Pharmaceuticals include Adicet Bio (ACET), Mustang Bio (MBIO), Theratechnologies (THERF), Fulcrum Therapeutics (FULC), Sernova (SEOVF), CorMedix (CRMD), Ovid Therapeutics (OVID), Infinity Pharmaceuticals (INFI), Taiwan Liposome (TLC), Enochian Biosciences (ENOB), Clever Leaves (CLVR), BELLUS Health (BLU), Clearside Biomedical (CLSD), Xeris Pharmaceuticals (XERS) and Sol-Gel Technologies (SLGL).
View all of GLMD's competitors.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (4.84%), Morgan Stanley (0.74%), Renaissance Technologies LLC (0.24%), Squarepoint Ops LLC (0.22%) and Goldman Sachs Group Inc. (0.11%).

Which major investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, and Renaissance Technologies LLC.

Which major investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Goldman Sachs Group Inc., and Morgan Stanley.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.03.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $76.00 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-28,770,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 18 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

Where are Galmed Pharmaceuticals' headquarters?

Galmed Pharmaceuticals is headquartered at 16 TIOMKIN STREET, TEL AVIV L3, 6578317.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here